Spring direct naar de hoofdnavigatie of de inhoud

Jennifer Ebner von Eschenbach

Patent attorney

“Investing that little extra time and effort in IP at the right moment makes your technology go further.”
Home / Experts / Jennifer Ebner von Eschenbach

Jennifer Ebner von Eschenbach

Jennifer Ebner von Eschenbach

  • Chemistry
  • Life Sciences
  • European Patent Attorney
  • Senior Associate

Jennifer Ebner von Eschenbach began her career as a European patent attorney in 1991 when she commenced her training in the Munich office of the international IP law firm of Ladas & Parry, LLP. Jennifer took over the office management from 1996-2008, during which time she was involved with the prosecution of patent applications for many multinational companies and research institutions. This provided her with an insight of IP needs covering a broad technological spectrum.

More information about Jennifer

Since joining V.O. in 2008, Jennifer has focused on developments in the pharmaceutical and chemical sectors, including novel therapies, diagnostic tools, (bio)technological processes for the employment of renewable resources, as well as environmentally-conscious chemical processes/products, again spanning both a broad range of technologies and clients.

Jennifer has a wide practical experience in procuring and defending patents, including the filing and defense of oppositions. Through the provision of opinions on patent validity and infringement, she also has considerable experience in advising on parties’ freedom to operate.

Working experience

  • Patent Attorney, V.O. (2008-present)
  • Patent Attorney, Ladas & Parry, LLP (1991-2008): Manager of office in Munich (1996-2008)
  • Post-Doctoral Research, Inorganic Chemical Institute of the Technical University of Munich (1989-1990)

Education

  • PhD in Chemistry, University of Melbourne (1988)
  • MSc in Chemistry, University of Melbourne (1984, with honours)

Publications

  • •Schmidbaur H., Ebner von Eschenbach J., Kumberger O., & Müller G., Cyclic Dinuclear Gold(I) Complexes: The Crystal Structure of Bis-µ-[(diphenylphosphino)(diphenylphosphinoselenoyl)methane]-digold(I) Bis(perchlorate), Chem. Ber., 123, 2261-2265, 1990
  • Bond A. M., Colton R., Ebner J., & Ellis S. R., Differences in Nature and Stability of Cadmium Complexes with Group 15/Group 16 Donor Ligands as Determined by Multinuclear (31P, 77Se, 113Cd) Magnetic Resonance and Electrochemical Techniques, Inorganic Chemistry, 28, 4509-4516, 1989
  • Colton R., Ebner J., & Hoskins B. F., Multinuclear Magnetic Resonance Studies of the Reactions of Bidentate Ligands with Pt(S2P{OEt}2)2. Crystal and Molecular Structure of (apeS)Pt(S2P{OEt}2)2 (ApeS = Ph2AsCH2CH2P(S)Ph2) , Inorganic Chemistry, 27, 1993-1999, 1988
  • Bond A. M., Colton R., & Ebner J., Multinuclear Magnetic Resonance (31P, 77Se, 199Hg) and Electrochemical Studies of Non-labile Mercury(II) Complexes with Group 15/Group 16 Donor Ligands, Inorganic Chemistry, 27, 1697-1702, 1988

Languages

  • German
  • English

Also see these experts

Marijke Westra

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
Wezenbeek, Bart van

Bart van Wezenbeek

  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate
More experts

News

The consequences of the Nagoya Protocol

  The Nagoya Protocol is highly relevant for the Dutch seed culture sector. But the content of the protocol is far from easy to understand. IP Leads summarises the main provisions for you and the most important consequences.Continue reading

No happy ending for a pharmaceutical company in a case involving a Native American tribe

In the case known as Mohawk tribe versus Mylan, the US Federal Circuit Court of Appeals ruled that patent holders cannot shield themselves from an “inter partes review” of a patent by assigning that patent to a Native American tribe. Ironically enough, this is due to the fact that the decision handed down by the […]Continue reading

Does the new law for the protection of trade secrets offer sufficient protection?

On 9 June, the new law for the protection of trade secrets came into force (based on European Directive 2016/943/EU). On the basis of the law, it is possible to take action against the illegal acquisition, use and disclosure of trade secrets. If a trade secret is misused, the holder can bring various actions based […]Continue reading

Events

European Biotech and Pharma Partnering Conference 2018

Osaka, Japan,Congres Convention Centre Second Basement, North Building, Grand Front Osaka

The European Biotech and Pharma Partnering Conference in Osaka offers business contacts to industry professionals who are looking for potential partners in the EU and Japan to ensure sustainable business development and growth. More about this event

BIO JAPAN 2018 – Flemish Life Sciences & Biotech Week

Pacifico Yokohama, 1 Chome-1 Minatomirai, Nishi Ward, Yokohama, Kanagawa, Japan

Asia's Premier Partnering Event for the Global Biotechnology Industry BioJapan has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades. More about this event

The London IP Summit 2018

Four Seasons Hotel London at Park Lane, Hamilton Place, Park Lane, London, Verenigd Koninkrijk

The London IP Summit is an industry leading event dedicated to bringing together IP owners, experts and investors to address key challenges and operational issues faced by companies and IP professionals today. More about this event